Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 48
Filter
1.
Finance Research Letters ; : 103275, 2022.
Article in English | ScienceDirect | ID: covidwho-1996173

ABSTRACT

This paper examines the impact of the COVID-19 pandemic on the adjustments of dividends and share repurchases of publicly listed firms in the G-7 countries. Firms in the United Kingdom, Germany, France, and Italy experienced a widespread cut in dividends, while firms in the United States and Canada cut cash payout more via share repurchases, with Japanese firms in between. Corporate cash holdings helped mitigate the negative impact of COVID on payout adjustments, but the impact was less significant for European firms.

2.
Front Psychol ; 13: 867599, 2022.
Article in English | MEDLINE | ID: covidwho-1952642

ABSTRACT

Physical activity has wide-ranging consequences for people's physical, mental, and social health. Although the beneficial effects of physical activity on well-being were widely studied, how it promotes well-being remained unclear. The present study utilized the measure of physical activity rating scale (PARS-3), flourishing scale (FS), Chinese- meaning in life questionnaire (C-MLQ), and general self-efficacy scale (GSES) to examine the connection between physical activity and flourishing and the multiple mediation effects of meaning and self-efficacy with 827 Chinese undergraduates. The results indicated that (a) physical activity positively predicted flourishing; (b) meaning in life and self-efficacy played mediating roles in physical activity and flourishing, separately and jointly. Our findings revealed the mechanism of physical activity fostering flourishing, thereby providing an empirical basis for promoting health and flourishing, especially during COVID-19.

3.
Aust J Gen Pract ; 512022 07 04.
Article in English | MEDLINE | ID: covidwho-1924949

ABSTRACT

The outbreak of the Omicron strain of COVID-19 led to the most restrictive lockdowns ever implemented in Shanghai.


Subject(s)
COVID-19 , General Practitioners , China/epidemiology , Communicable Disease Control , Disease Outbreaks/prevention & control , Humans
4.
Chem Soc Rev ; 51(10): 3828-3845, 2022 May 23.
Article in English | MEDLINE | ID: covidwho-1795656

ABSTRACT

The great success achieved by the two highly-effective messenger RNA (mRNA) vaccines during the COVID-19 pandemic highlights the great potential of mRNA technology. Through the evolution of mRNA technology, chemistry has played an important role from mRNA modification to the synthesis of mRNA delivery platforms, which allows various applications of mRNA to be achieved both in vitro and in vivo. In this tutorial review, we provide a summary and discussion on the significant progress of emerging mRNA technologies, as well as the underlying chemical designs and principles. Various nanoparticle (NP)-based delivery strategies including protein-mRNA complex, lipid-based carriers, polymer-based carriers, and hybrid carriers for the efficient delivery of mRNA molecules are presented. Furthermore, typical mRNA delivery platforms for various biomedical applications (e.g., functional protein expression, vaccines, cancer immunotherapy, and genome editing) are highlighted. Finally, our insights into the challenges and future development towards clinical translation of these mRNA technologies are provided.


Subject(s)
COVID-19 , Nanoparticles , COVID-19/therapy , Humans , Immunotherapy , Nanoparticles/chemistry , Pandemics , Proteins , RNA, Messenger/genetics , RNA, Messenger/metabolism
5.
J Imaging ; 8(3)2022 Mar 05.
Article in English | MEDLINE | ID: covidwho-1732094

ABSTRACT

Ultrasound imaging of the lung has played an important role in managing patients with COVID-19-associated pneumonia and acute respiratory distress syndrome (ARDS). During the COVID-19 pandemic, lung ultrasound (LUS) or point-of-care ultrasound (POCUS) has been a popular diagnostic tool due to its unique imaging capability and logistical advantages over chest X-ray and CT. Pneumonia/ARDS is associated with the sonographic appearances of pleural line irregularities and B-line artefacts, which are caused by interstitial thickening and inflammation, and increase in number with severity. Artificial intelligence (AI), particularly machine learning, is increasingly used as a critical tool that assists clinicians in LUS image reading and COVID-19 decision making. We conducted a systematic review from academic databases (PubMed and Google Scholar) and preprints on arXiv or TechRxiv of the state-of-the-art machine learning technologies for LUS images in COVID-19 diagnosis. Openly accessible LUS datasets are listed. Various machine learning architectures have been employed to evaluate LUS and showed high performance. This paper will summarize the current development of AI for COVID-19 management and the outlook for emerging trends of combining AI-based LUS with robotics, telehealth, and other techniques.

7.
EuropePMC; 2020.
Preprint in English | EuropePMC | ID: ppcovidwho-325349

ABSTRACT

COVID-19 outbreak first reported in Wuhan has been officially declared as a global pandemic. Considering the fecal shedding of SARS-CoV-2 has been proven by the viral strains isolated from COVID-19 patient’s stool specimens, it proposed the possibility that contaminated wastewater and fomites might involve in the disease transmission in outbreak cities. In this study, we collected the wastewater samples collected from COVID-19 designated hospitals, Fangcang shelter hospitals, quarantine spots and wastewater treatment plants in Wuhan, China, and performed RT-qPCR and droplet digital PCR (ddPCR) for the detection of SARS-CoV-2. Although high concentration of residual chlorine for disinfection of SARS-CoV-2 is persisted, low level SARS-CoV-2 RNA can be detected by qPCR and droplet digital PCR (ddPCR) in the wastewater samples during the COVID-19 outbreak. This preliminary data firstly described in China implies the potential transmission risk of SARS-CoV-2 through medical wastewater in the cities during the COVID-19 outbreak, which calls particular attention for the surveillance and efficient disinfection of wastewater from COVID-19 related facilities.

8.
EuropePMC; 2021.
Preprint in English | EuropePMC | ID: ppcovidwho-325222

ABSTRACT

BACKGROUND: Previous study suggested that Chinese Herbal Medicine (CHM) Formula Huashibaidu granule might shorten disease course of Corona Virus Disease 2019 (COVID-19) patients. Our research aims to investigate the early treatment effect of Huashibaidu granule in mild COVID-19 patients under well clinical management.METHODS: An unblended cluster-randomized clinical trial was conducted at the Dongxihu FangCang hospital. 2 cabins were randomly allocated to CHM or control group, with 204 randomly sampled mild COVID-19 patients in each cabin. All participants received a 7-day conventional treatment, and CHM group cabin used additional Huashibaidu granule 10g twice daily. Participants were followed up until they met clinical endpoint. The primary outcome was patient become worsening before clinical endpoint occurred. The secondary outcomes was discharge with cure before clinical endpoint occurred and relief of composite symptoms after 7 days treatment.FINDINGS: All 408 participants were followed up to meet clinical endpoint and included in statistical analysis. The baseline characteristics were comparable between 2 groups. The number of worsening patients in the CHM group was 5 (2.5%), and that in the control group was 16 (7.8%). There was a significant difference between groups (P=0.014). 8 foreseeable mild adverse events occurred without statistical difference between groups.INTERPRETATION: 7-day early treatment with Huashibaidu granule reduced worsening conversion of mild COVID-19 patients. Our study supports Huashibaidu Granule as an active option for early treatment of mild COVID-19 in similar medical locations with well management.TRIAL REGISTRATION: The Chinese Clinical Trial Registry: ChiCTR2000029763.FUNDING: This study was supported by “National Key R&D Program of China” (No.2020YFC0841500).DECLARATION OF INTERESTS: The authors guaranteed that there existed no competing interest in this paper.ETHICS APPROVAL STATEMENT: Ethics Review Committee of Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Approval of Ethical Review Acceptance Number: S2020-001;Approval Number: P20001/PJ01.

9.
EuropePMC; 2020.
Preprint in English | EuropePMC | ID: ppcovidwho-323673

ABSTRACT

Background: To explore the kinetic changes in virology, specific antibody response and imaging during the clinical course of COVID-19. Methods: : This observational study enrolled 20 patients with COVID-19, who were hospitalized between January 20-April 6, 2020, in the two COVID-19 designated hospitals of Zhoushan, Zhejiang and Rushan, Shandong, China, The laboratory findings, imaging, serum response to viral infection, and viral RNA level in the throat and stool samples were assessed from onset to recovery phase in patients with COVID-19. Results: : SARS-COV-2 RNA was positive as early as day four. It remained positive until day 55 post-onset in the sputum-throat swabs and became negative in most cases (55%) within 14 days after onset. Lymphocytopenia occurred in 40% (8/20) of patients during the peak infection period and returned to normal at week five. The most severe inflammation in the lungs appeared in week 2 or 3 after onset, and this was completely absorbed between week 6 and 8 in 85.7% of patients. All patients had detectable antibodies to the receptor binding domain (RBD), and 95% of these patients had IgG to viral N proteins. The antibody titer peaked at week four. Anti-S IgM was positive in 7 of 20 patients after week three. Conclusions: : All COVID-19 patients in this study were self-limiting and recovered well though it may take as long as 6-8 weeks. Our findings on the kinetic changes in imaging, serum response to viral infection and viral RNA level may help understand pathogenesis and define clinical course of COVID-19.

10.
EuropePMC; 2021.
Preprint in English | EuropePMC | ID: ppcovidwho-322509

ABSTRACT

Background: Avoid touching our eyes, nose, and mouth (T-zone) is one of recommended strategies to reduce the spread of the coronavirus disease 2019 (COVID-19) and other infectious diseases. However, face-touching is a frequent behaviour, and it is often done automatically without self-awareness. Raising self-awareness of habituated face-touching behaviour may help individuals to avoid face-touching by contaminated hands. Our aim was to evaluate whether mindfulness-based brief behaviour-change intervention (MBI) named “STOP (Stop, Take a Breath, Observe, Proceed) touching your face” can reduce face-touching behavior. Methods: In this online-based, two group, wait-list, randomized controlled trial, participants aged 18 years or more from general population in China were recruited via Chinese social media platforms. Eligible participants were randomly assigned in a 1:1 ratio to receive “STOP touching your face” intervention or control intervention. Those researchers who assessing outcomes were masked to group allocation. A 60-minute self-monitoring of face-touching behaviour was required to report in the pre- and post-intervention. Reduction of percentage of T-Zone touching was set as primary outcome, with reduction of face-touching frequency being a key secondary outcome. These outcomes were analysed in the intention-to-treat (ITT) basis with a complete case analysis (CCA). Safety was monitored in all randomly assigned participants. This trial is registered at ClinicalTrials.gov (Trial registration number: NCT04330352), and is completed. Findings: Between April 2, 2020 to July 2, 2020, 10194 participants were invited to the trial. Of these, we recruited and randomly assigned 1090 (10.7%) participants to the “STOP touching your face” intervention group (n=545) or to the wait-list control intervention (comparator) group (n=545) after reporting the first 60-minute self-monitoring of face-touching behaviour (pre-intervention). Among them, 71.6% (n=390) participants from the intervention group and 63.9% (n=348) from the control group reported the second 60-minute self-monitoring of face-touching behaviour (post-intervention). ITT analysis revealed that percentage of T-Zone touching was significantly reduced by 8.1% in the intervention group (from 81.1% to 73.0%, RR=0.901, OR=0.631, RD=-0.081, p=0.002), and insignificantly reduced by 0.6% in the control intervention (from 80.0% to 79.4%, p=0.821). Group comparison showed that fewer participants had T-Zone touching in the intervention group than that in the control group (73.0% vs 79.4%, RR=0.919, OR=0.700, RD=-0.064, p=0.015) after intervention, and that there was more reduction of T-Zone touching frequency in the intervention group than that in the control group (mean ± SD: 1.7 ± 5.13 vs 0.7 ± 3.98, Mean difference (95% CI): 1.03 (0.48 to 1.58), p<0.001, Cohen's d=-0.218). The above results were further confirmed by CCA. Compared with older individuals (≥30 years old), young adults (18–29 years old) have twice risk of having T-Zone touching behaviour (OR=2.029, 95% CI=1.145 to 3.597, p=0.015), and younger participants reduced face-touching frequency more than their older counterparts (mean ± SD: 9.9 ± 14.24 vs 3.6 ± 11.25, Mean difference (95% CI)=6.270 (3.615 to 8.924), p<0.001, Cohen's d=-0.47). Interpretation This trial is the first to evaluate the efficacy of “STOP touching your face” intervention to reduce face-touching behaviour during the outbreak of COVID-19. The findings of significantly reduced T-Zone touching behaviour in the intervention group supports the widely dissemination of this brief and simple mindfulness-based behaviour-change intervention to low the risk for the COVID-19 and other hand-to face-touching infectious diseases.Trial registration number: NCT04330352Trial Registration. Funding: Zhejiang University, number (2020XGZX046). Declaration of Interest: We declare no competing interests.Ethical Approval: The trial was approved by The Ethics Committee of Sir Run Run Sha hospital, an affiliate of Zhejiang University, Medical College (NO. 20200401-32).

11.
EuropePMC; 2020.
Preprint in English | EuropePMC | ID: ppcovidwho-312638

ABSTRACT

Background: A novel coronavirus caused an outbreak of acute infectious pneumonia are spreading over the globe. However, studies predicting prognosis are limited. We predicted outcomes of patients with coronavirus disease 2019 (COVID-19) using the neutrophil-to-lymphocyte ratio (NLR) on admission. Methods: : We retrospectively analyzed the characteristics of COVID-19 patients diagnosed from February 6 to March 1. The outcomes, including the occurrence of in-hospital mortality, acute kidney injury (AKI), and endotracheal intubation (ETI), were recorded. The relationships of neutrophils, lymphocytes, C-reactive protein, lactate dehydrogenase, and NLR with outcomes were assessed using multivariate regression model. P -values for trends across quartiles of NLR was examined. Results: : A total of 182 patients were included. 37 (20.3%) patients died during the hospitalization, 41 (22.5%) developed AKI, and 36 (19.8%) received ETI. The NLR had a superior predictive performance than others. Using an NLR cutoff of 11.4, the area under the curves (AUC) were 0.766 for in-hospital mortality, 0.755 for AKI, and 0.733 for ETI. In multivariate analysis, NLR >11.4 was further identified as an independent prognostic factor. Following stratification with quartiles of NLR, a positive trend between the increasing quartiles of NLR and the three outcomes were observed ( p -values for trends across quartiles were 0.043, <0.001, and 0.041, respectively). The multivariate adjusted odds ratio (OR) in the highest quartile vs. the lowest quartile were 5.738 for mortality, 25.307 for AKI, and 5.136 for ETI. Conclusions: : Increasing NLR obtained on admission is a powerful predictor for inpatient mortality, AKI, and ETI in COVID-19 patients.

12.
EuropePMC; 2020.
Preprint in English | EuropePMC | ID: ppcovidwho-307595

ABSTRACT

The current spreading novel coronavirus SARS-CoV-2 is highly infectious and pathogenic and has attracted global attention. Recent studies have found that SARS-CoV-2 and SARS-CoV share around 80% of homology and use the same cell entry receptor, ACE2. These inspired us to study other receptors of SARS-CoV, which may be used for SARS-CoV-2 binding as well. In this study, we screened the gene expression of three receptors (ACE2, DC-SIGN and L-SIGN) in four datasets of normal lung tissue from lung adenocarcinoma patients and two single-cell RNA sequencing datasets from normal lung and bronchial epithelial cells separately. No significant difference in gene expression of these three receptors were found between gender groups (male vs female). We found higher gene expression of DC-SIGN in elder with age>60 and higher gene expression of L-SIGN in Caucasian than Asian. Similar to ACE2, we observed significantly higher DC-SIGN gene expression in the lungs of smokers, especially former smokers. However, smokers upregulate ACE2 and DC-SIGN gene expression in different cell types. In the whole lung, ACE2 is actively expressed in remodeled Alveolar Type II cells of former smokers, while DC-SIGN is largely expressed in monocytes of former smokers and dendritic cells of current smokers. In bronchial epithelium, no obvious gene expression of DC-SIGN and L-SIGN was observed while ACE2 was found to be actively expressed in goblet cells of current smokers and club cells of non-smokers. In conclusion, our findings may indicate that smokers, especially former smokers, and people over 60 have higher risk and are more susceptible to SARS-CoV-2 infection. Also, this study provides hints on possible SARS-CoV-2 pathogenicity mechanisms in lung infection.

13.
Database (Oxford) ; 20222022 01 17.
Article in English | MEDLINE | ID: covidwho-1672169

ABSTRACT

In recent years, efficient scRNA-seq methods have been developed, enabling the transcriptome profiling of single cells massively in parallel. Meanwhile, its high dimensionality and complexity bring challenges to the data analysis and require extensive collaborations between biologists and bioinformaticians and/or biostatisticians. The communication between these two units demands a platform for easy data sharing and exploration. Here we developed Single-Cell Transcriptomics Annotated Viewer (SCANNER), as a public web resource for the scientific community, for sharing and analyzing scRNA-seq data in a collaborative manner. It is easy-to-use without requiring special software or extensive coding skills. Moreover, it equipped a real-time database for secure data management and enables an efficient investigation of the activation of gene sets on a single-cell basis. Currently, SCANNER hosts a database of 19 types of cancers and COVID-19, as well as healthy samples from lungs of smokers and non-smokers, human brain cells and peripheral blood mononuclear cells (PBMC). The database will be frequently updated with datasets from new studies. Using SCANNER, we identified a larger proportion of cancer-associated fibroblasts cells and more active fibroblast growth-related genes in melanoma tissues in female patients compared to male patients. Moreover, we found ACE2 is mainly expressed in lung pneumocytes, secretory cells and ciliated cells and differentially expressed in lungs of smokers and never smokers.


Subject(s)
COVID-19 , Leukocytes, Mononuclear , Female , Gene Expression Profiling , Humans , Male , RNA-Seq , SARS-CoV-2 , Sequence Analysis, RNA , Single-Cell Analysis , Software
14.
J Nat Prod ; 85(2): 327-336, 2022 02 25.
Article in English | MEDLINE | ID: covidwho-1655431

ABSTRACT

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to more than 5 million deaths worldwide to date. Due to the limited therapeutic options so far available, target-based virtual screening with LC/MS support was applied to identify the novel and high-content compounds 1-4 with inhibitory effects on SARS-CoV-2 in Vero E6 cells from the plant Dryopteris wallichiana. These compounds were also evaluated against SARS-CoV-2 in Calu-3 cells and showed unambiguous inhibitory activity. The inhibition assay of targets showed that compounds 3 and 4 mainly inhibited SARS-CoV-2 3CLpro, with effective Kd values. Through docking and molecular dynamics modeling, the binding site is described, providing a comprehensive understanding of 3CLpro and interactions for 3, including hydrogen bonds, hydrophobic bonds, and the spatial occupation of the B ring. Compounds 3 and 4 represent new, potential lead compounds for the development of anti-SARS-CoV-2 drugs. This study has led to the development of a target-based virtual screening method for exploring the potency of natural products and for identifying natural bioactive compounds for possible COVID-19 treatment.


Subject(s)
Antiviral Agents/pharmacology , Biological Products/pharmacology , Microbial Sensitivity Tests/methods , Phloroglucinol/pharmacology , SARS-CoV-2/drug effects , Terpenes/pharmacology , Chromatography, High Pressure Liquid , Chromatography, Liquid , Crystallography, X-Ray , Drug Delivery Systems , Dryopteris/chemistry , Magnetic Resonance Spectroscopy , Mass Spectrometry , Molecular Docking Simulation , Molecular Structure , Virtual Reality
15.
EuropePMC; 2021.
Preprint in English | EuropePMC | ID: ppcovidwho-296347

ABSTRACT

There is a continuously growing demand for emergency department (ED) services across the world, especially under the COVID-19 pandemic. Risk triaging plays a crucial role in prioritizing limited medical resources for patients who need them most. Recently the pervasive use of Electronic Health Records (EHR) has generated a large volume of stored data, accompanied by vast opportunities for the development of predictive models which could improve emergency care. However, there is an absence of widely accepted ED benchmarks based on large-scale public EHR, which new researchers could easily access. Success in filling in this gap could enable researchers to start studies on ED more quickly and conveniently without verbose data preprocessing and facilitate comparisons among different studies and methodologies. In this paper, based on the Medical Information Mart for Intensive Care IV Emergency Department (MIMIC-IV-ED) database, we proposed a public ED benchmark suite and obtained a benchmark dataset containing over 500,000 ED visits episodes from 2011 to 2019. Three ED-based prediction tasks (hospitalization, critical outcomes, and 72-hour ED revisit) were introduced, where various popular methodologies, from machine learning methods to clinical scoring systems, were implemented. The results of their performance were evaluated and compared. Our codes are open-source so that anyone with access to MIMIC-IV-ED could follow the same steps of data processing, build the benchmarks, and reproduce the experiments. This study provided insights, suggestions, as well as protocols for future researchers to process the raw data and quickly build up models for emergency care.

16.
Journal of Food Safety and Quality ; 12(19):7831-7839, 2021.
Article in Chinese | CAB Abstracts | ID: covidwho-1519509

ABSTRACT

In recent years, the import of aquatic products at Zhanjiang port has continued to increase, which has effectively promoted the development of the local economy. However, unqualified imported aquatic products have occurred from time to time, and it has always been an important duty of the customs to control the safety of imported food. Especially with the continuous outbreak of novel coronavirus pneumonia epidemic situation since 2020, it is particularly important to ensure the quality and safety of imported aquatic products, especially the traceability of the products. This article focused on analyzing the characteristics and functions of blockchain technology, combining with the problems of traceability of imported aquatic products in Zhanjiang, combined blockchain technology with three-dimensional customs supervision, explored the establishment of customs blockchain supervision model, and analyzed and studied the feasibility of the application of blockchain in the traceability of imported aquatic products in Zhanjiang. The traceability supervision system including production enterprises, importers and exporters, third-party institutions, logistics, warehousing, banking, insurance and other stakeholders was constructed. Finally, relevant application exploration schemes were put forward, and it was expected to provide some reference for improving the quality of imported products and perfecting the construction of imported food safety traceability management system.

17.
J Med Internet Res ; 23(9): e18307, 2021 09 16.
Article in English | MEDLINE | ID: covidwho-1443931

ABSTRACT

Internet hospitals, as a new forum for doctors to conduct diagnosis and treatment activities based on the internet, are emerging in China and have become integral to the development of the medical field in conjunction with increasing reforms and policies in China's medical and health system. Here, we take the Internet Hospital of the First Affiliated Hospital, Zhejiang University (FAHZU Internet Hospital) as an example to discuss the operations and functional positioning of developing internet hospital medical services in relation to physical hospitals. This viewpoint considers the platform operation, management, and network security of FAHZU Internet Hospital, and summarizes the advantages and limitations in the operation to provide a reference for other areas with interest in developing internet hospitals.


Subject(s)
Telemedicine , China , Hospitals , Humans , Internet
18.
J Med Cases ; 12(5): 181-185, 2021 May.
Article in English | MEDLINE | ID: covidwho-1374671

ABSTRACT

Primary breast diffuse large B-cell lymphoma (PB-DLBCL) is a rare localized extranodal lymphoma. It is mainly diagnosed by pathological examination due to the lack of specific clinical and imaging manifestations. Whole-body positron emission tomography-computed tomography (PET-CT) is widely used in determining clinical staging and guiding clinical treatment. As part of comprehensive treatment, targeted therapy with rituximab, intrathecal methotrexate injection and consolidation radiotherapy remain controversial in treating PB-DLBCL, but the comprehensive treatment based on full-course of chemotherapy is still widely used as the first-line treatment. Comprehensive treatment often leads to a sharp decline in the immunity of elderly patients with malignancy. In this situation, surgery may be a good chance to improve their life quality without serious complications. We present a rare case of PB-DLBCL during the coronavirus disease 2019 (COVID-19) pandemic. The patient underwent chest CT scan to screen COVID-19 and a mass of left breast was accidentally found. Because of the city lockdown policy in Wuhan, she did not seek medical help until noticing that the mass was gradually enlarged. Both ultrasonography and mammography indicated that the lesion was breast cancer. However, ultrasound-guided core needle biopsy revealed diffuse large B-cell lymphoma of breast and PET-CT scan showed that the lesion was a primary hypermetabolic tumor of left breast. The patient subsequently received comprehensive treatment based on six cycles of rituximab-cyclophosphamide, hydroxydaunomycin, oncovin, prednisone (R-CHOP) chemotherapy.

19.
Gynecologic Oncology ; 162:S98-S98, 2021.
Article in English | Academic Search Complete | ID: covidwho-1366724

ABSTRACT

The objective of this retrospective review was to assess barriers to successful clinical trial enrollment among gynecologic cancer patients at a comprehensive cancer center. A retrospective chart review was performed of all new patients and established patients requiring treatment changes seen in a clinic setting by physicians in the gynecologic oncology department at a national cancer institute between July 1, 2019, and June 30, 2020. Demographic information collected for each patient included age, race, language, distance from the cancer center, insurance type, marital status, education, performance status and medical history. Demographic factors were compared between patients who enrolled in trials and those who were deemed eligible for clinical trials but did not enroll. Patients who did not enroll in a clinical trial were stratified by the reason for not enrolling as physician factor, patient factor, trial factor, and screening failure. Data was collected in a secure REDCap database. Data was analyzed using the Wilcoxon rank sum test and Fisher's exact test. 960 records were reviewed and 165 patients were found to be eligible for a clinical trial at the time of their visit. 35 of these 165 patients (21.2%) enrolled in a clinical trial. Among patients who did not enroll in a clinical trial, the reasons for not doing so were due to a physician factor (71/130 or 55%), patient factor (42/130 or 32%), screening failure (13/130 or 10%), or a trial factor (4/130 or 3%). There were no significant differences in demographics between patients who enrolled in trials and those who did not. Patients who did not enroll secondary to a physician factor differed significantly from those enrolled or attempted to enroll in age and insurance type. Patients who did not enroll secondary to a physician factor were older when compared to those who enrolled or attempted to enroll in a clinical trial but failed the screening process (median of 70 vs 61.5 years old, p=0.014). They were also more likely to have Medicare and less likely to have private insurance (p=0.044). Patients who did not enroll secondary to a patient factor did not appear to differ significantly from patients who did enroll or who failed screening. Although patients who did not enroll secondary to a patient factor lived a mean distance almost twice as far away as those who enrolled or attempted to enroll (mean of 184 vs 91 miles), this was not statistically significant (p=0.107). Based on a one year time span of retrospective review, including the COVID 19 pandemic time, physician factor and concern for a patient's age appears to be the biggest barrier to clinical trial enrollment. Exploring additional reasons behind physicians' reluctance to enroll patients in trials may be the key to increasing clinical trial enrollment of eligible patients. [ABSTRACT FROM AUTHOR] Copyright of Gynecologic Oncology is the property of Academic Press Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

20.
Clin Breast Cancer ; 22(1): e1-e7, 2022 01.
Article in English | MEDLINE | ID: covidwho-1252588

ABSTRACT

BACKGROUND: The coronavirus disease 2019 pandemic is a global public health event. Wuhan used to be the epicenter of China and finally controlled the outbreak through city lockdown and many other policies. However, the pandemic and the prevention strategies had a huge impact on the medical care procedures for patients with breast cancer, leading to the delay or interruption of anticancer therapies. PATIENTS AND METHODS: To better serve patients with breast cancer under the premise of epidemic control, many strategies have been proposed and optimized in our center. One of the most important parts of these strategies is the promotion of telemedicine, including online consultation, online prescription, and drug mailing services. RESULTS: In keeping with the city and hospital policies, we have also introduced stricter ward management policies and more precise care. CONCLUSION: Here, we collected the diagnosis and treatment process of patients with breast cancer in our center during the coronavirus disease 2019 pandemic, which was found to be correlated to a reduction in chemotherapy-related myelosuppression and hepatic dysfunction, hoping to provide a reference for other cancer centers that may suffer from the similar situation.


Subject(s)
Breast Neoplasms/drug therapy , COVID-19/epidemiology , SARS-CoV-2 , Adult , Aged , Antineoplastic Agents/adverse effects , Bone Marrow/drug effects , Breast Neoplasms/diagnosis , Breast Neoplasms/pathology , Chemical and Drug Induced Liver Injury/etiology , China/epidemiology , Female , Humans , Middle Aged , Telemedicine
SELECTION OF CITATIONS
SEARCH DETAIL